Log in

NASDAQ:CDMO - Avid Bioservices Stock Price, Forecast & News

$7.18
-0.05 (-0.69 %)
(As of 02/23/2020 10:58 AM ET)
Today's Range
$7.05
Now: $7.18
$7.29
50-Day Range
$6.31
MA: $6.71
$7.27
52-Week Range
$3.37
Now: $7.18
$8.38
Volume221,207 shs
Average Volume239,499 shs
Market Capitalization$404.52 million
P/E RatioN/A
Dividend YieldN/A
Beta2.81
Avid Bioservices, Inc, a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDMO
CUSIPN/A
Phone714-508-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.60 million
Book Value$0.95 per share

Profitability

Net Income$-4,220,000.00

Miscellaneous

Employees185
Market Cap$404.52 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.


Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Avid Bioservices shares reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices Inc (NASDAQ:CDMO) issued its quarterly earnings results on Monday, December, 9th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.01. The biopharmaceutical company had revenue of $18.31 million for the quarter, compared to analysts' expectations of $14.34 million. Avid Bioservices had a negative net margin of 6.83% and a negative return on equity of 8.78%. The company's revenue was up 79.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.05) earnings per share. View Avid Bioservices' Earnings History.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Avid Bioservices.

What price target have analysts set for CDMO?

5 Wall Street analysts have issued 12-month target prices for Avid Bioservices' shares. Their forecasts range from $7.50 to $11.00. On average, they anticipate Avid Bioservices' share price to reach $9.90 in the next year. This suggests a possible upside of 37.9% from the stock's current price. View Analyst Price Targets for Avid Bioservices.

What is the consensus analysts' recommendation for Avid Bioservices?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avid Bioservices.

What are Wall Street analysts saying about Avid Bioservices stock?

Here are some recent quotes from research analysts about Avid Bioservices stock:
  • 1. According to Zacks Investment Research, "Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It also offer process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. Avid Bioservices Inc., formerly known as Peregrine Pharmaceuticals Inc., is based in TUSTIN, United States. " (11/12/2019)
  • 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating with a price target of $11. Our valuation is based on a discounted EBITDA model, which we believe takes into account both the established and anticipated revenue growth of Avid, which is the cornerstone of the company’s business. We assign a 23x multiple on F2023 EBIDTA discounted back at Avid’s WACC of 13%." (7/8/2019)

Has Avid Bioservices been receiving favorable news coverage?

Press coverage about CDMO stock has been trending very negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avid Bioservices earned a media sentiment score of -3.6 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Avid Bioservices.

Who are some of Avid Bioservices' key competitors?

What other stocks do shareholders of Avid Bioservices own?

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the folowing people:
  • Dr. Roger J. Lias, Pres, CEO & Director (Age 59)
  • Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Mr. Daniel R. Hart, Chief Financial Officer (Age 46)
  • Mr. Stephen Michael Hedberg, Sr. Director of Fin. & SEC Reporting and Principal Financial & Accounting Officer (Age 44)
  • Ms. Lorna Larson, Sr. Director of HR

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different of institutional and retail investors. Top institutional investors include AltraVue Capital LLC (3.93%), State Street Corp (1.88%), Sargent Investment Group LLC (1.71%), Sargent Investment Group LLC (1.59%), Geode Capital Management LLC (1.24%) and Essex Investment Management Co. LLC (0.80%). Company insiders that own Avid Bioservices stock include Joel Mccomb, Joseph Carleone and Richard B Hancock. View Institutional Ownership Trends for Avid Bioservices.

Which institutional investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Geode Capital Management LLC, Schonfeld Strategic Advisors LLC, Crestwood Advisors Group LLC, Jefferies Group LLC, AltraVue Capital LLC, New York State Common Retirement Fund and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Avid Bioservices.

Which institutional investors are buying Avid Bioservices stock?

CDMO stock was acquired by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, EAM Global Investors LLC, Sargent Investment Group LLC, Renaissance Technologies LLC, Oxford Asset Management LLP, Parkman Healthcare Partners LLC, Bank of Montreal Can and EAM Investors LLC. Company insiders that have bought Avid Bioservices stock in the last two years include Joseph Carleone and Richard B Hancock. View Insider Buying and Selling for Avid Bioservices.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $7.18.

How big of a company is Avid Bioservices?

Avid Bioservices has a market capitalization of $404.52 million and generates $53.60 million in revenue each year. The biopharmaceutical company earns $-4,220,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Avid Bioservices employs 185 workers across the globe.View Additional Information About Avid Bioservices.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is http://www.avidbio.com/.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]


MarketBeat Community Rating for Avid Bioservices (NASDAQ CDMO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  298 (Vote Underperform)
Total Votes:  623
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel